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It has been challenging to generate in vitromodels of alveolar lung diseases, as the stable culture of alveolar type 2 (AT2) cells has been
difficult. Methods of generating and expanding AT2 cells derived from induced pluripotent stem cells (iPSCs) have been established and
are expected to be applicable to diseasemodeling. Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder characterized by
dysfunction of lysosome-related organelles, such as lamellar bodies (LBs), in AT2 cells. From anHPS type 2 (HPS2) patient, we established
disease-specific iPSCs (HPS2-iPSCs) and their gene-corrected counterparts. By live cell imaging, the LB dynamics were visualized and
altered distribution, enlargement, and impaired secretion of LBs were demonstrated in HPS2-iPSC-derived AT2 cells. These findings pro-
vide insight into the AT2 dysfunction in HPS patients and support the potential use of human iPSC-derived AT2 cells for future research
on alveolar lung diseases.
INTRODUCTION
Alveolar type2 (AT2) cells are tissue stemcells thatmaintain
homeostasis of the alveolar region of the lung (Barkauskas
et al., 2013). They secrete pulmonary surfactant to prevent
alveolar collapse and contribute to the host defense of the
lung (Whitsett et al., 2015). Lamellar bodies (LBs), charac-
teristic organelles of mature AT2 cells, are lysosome-related
organelles (LROs) involved in the storage and secretion of
pulmonary surfactant and are often affected in alveolar
lung diseases, including hereditary pulmonary fibrosis
(PF) (Nakatani et al., 2000; Whitsett et al., 2015). However,
the mechanism underlying the LB degeneration and AT2
cell dysfunction in human alveolar lung diseases is not
well understood due to poor accessibility and the difficulty
of isolatingandculturingprimaryAT2cells. Inducedplurip-
otent stem cells (iPSCs) are expected to overcome these lim-
itations. We previously established methods for generating
human pluripotent stem cell (hPSC)-derived alveolar and
airway cells in organoids (Gotoh et al., 2014; Konishi
et al., 2016) and successfully expanded hPSC-derived AT2
cells in alveolar organoids (AOs) (Yamamoto et al., 2017).
Hermansky-Pudlak syndrome (HPS) is a rare autosomal
recessive hereditary disease caused by mutations in the
genes involved in the formation and maturation of
LROs and characterized by oculocutaneous albinism and
bleeding diathesis (El-Chemaly and Young, 2016). Among
the ten subtypes, patients with HPS1, HPS2, and HPS4
can suffer from PF. HPS is a disease of LROs, and the
abnormal enlargement of LBs in AT2 cells was reported in
both HPS patients (Nakatani et al., 2000) and mouse
models (Lyerla et al., 2003). HPS2 is an extremely rare sub-
type of HPS that is caused by mutations of the AP3B1 gene,
which encodes the b3A subunit of the AP-3 complex,
which is involved in intracellular membrane traffic. It
was previously reported that approximately 40% of HPS2
patients had PF and that 78% of HPS2 patients with PF
were children (Jessen et al., 2013).
In this study, we generated HPS2 patient-derived iPSCs
(HPS2-iPSCs) and gene-corrected iPSCs (cHPS2-iPSCs) and
differentiated them into AOs (HPS2-AOs and cHPS2-AOs,
respectively). Based on the comparison of these AOs, we
report the AT2 cell dysfunction of HPS2-AOs.
RESULTS
Generation of HPS2-iPSCs and cHPS2-iPSCs
HPS2-iPSCs were established from patient fibroblasts ob-
tained from the Coriell Institute for Medical Research
(GM17890) (Figure 1A). The HPS2 patient donor had
compound heterozygous nonsense mutations in exon
15 and 18 of the AP3B1 gene and he was histologically
diagnosed with nonspecific interstitial pneumonitis at
20 months of age (Huizing et al., 2002) (Figure 1B).
Next, cHPS2-iPSCs were generated from HPS2-iPSCs by
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using CRISPR/Cas9-mediated homologous recombination
(Li et al., 2015) (Figure 1C). We targeted the mutation on
exon 18, because it was not possible to design a single guide
RNA to hybridize with the mutation on exon 15. After
G418 selection and limiting dilution, 36 out of 132 clones
(27%) had the donor template at the target locus. After Cre
excision, we chose a res69-5 clone for the subsequent ex-
periments. The sequencing data showed that the mutation
in exon 18 was corrected in cHPS2-iPSCs (Figures 1D and
S1A). There were no indels at 58 predicted off-target sites
(Table S1). The AP3B1 transcript level was decreased to
14% ± 5% in HPS2-iPSCs and restored to 75% ± 10% in
cHPS2-iPSCs, in comparison with normal control iPSCs
(Figure 1E), which was indicative of nonsense-mediated
mRNA decay (NMD) in HPS2-iPSCs, as reported in donor
cells (Huizing et al., 2002). In immunofluorescence (IF)
staining, the b3A subunit was almost absent in HPS2-iPSCs
and was restored in cHPS2-iPSCs (Figure 1F). Western blot-
ting demonstrated the absence of AP3B1 and the decrease
of AP3M1 in HPS2-iPSCs, consistent with the previous
report by Kook et al. (2018) (Figure S1B). Both HPS2-iPSCs
and cHPS2-iPSCs expressed undifferentiated markers and
showed no abnormal karyotypes (Figures S1C and S1D).
The pluripotency was demonstrated by the teratoma for-
mation (Figure S1E) and there was no integration of reprog-
ramming vectors in genomic DNA (Figure S1F). CD63 mol-
ecules interact with AP-3 complex via its tyrosine-based
targeting motif and are sorted to lysosomes (Rous et al.,
2002). Since CD63 is mis-sorted to the cell surface in AP-3
dysfunction, the function of AP-3 complex is assayable
by flow cytometry of CD63 (Dell’Angelica et al., 1999). In
HPS2-iPSCs, the increased cell surface CD63 expression
was observed in comparison with control iPSCs and
cHPS2-iPSCs, suggesting the dysfunction of AP-3 complex
in HPS2-iPSCs and its restoration in cHPS2-iPSCs (Figures
1G and 1H).
Comparison of the Methods of NKX2-1+ Cell Isolation
The isolation of NKX2-1+ lung progenitor cells is a critical
step in the generation of lung epithelial cells from hPSCs.
We compared the isolation efficiency of previously re-
ported sorting methods, carboxypeptidase M (CPM) and
CD47 combined with or without CD26 (Figure S2A) (Go-
toh et al., 2014; Hawkins et al., 2017). At day 21 of our in-
duction protocol (Figure 2A), CPMhigh cells contained the
most NKX2-1+ cells in all hPSC lines (Figures S2B and
S2C). Since there was no interaction between the cell lines
and sorting methods analyzed by two-way ANOVA, the
samples from different cell lines were all analyzed together.
As a result, CPM-based sorting was able to isolate more
NKX2-1+ cells than CD47-based methods (Figure S2D).
Induction of AOs from HPS2-iPSCs and cHPS2-iPSCs
Upon CPM-based sorting, NKX2-1+ lung progenitor cells
derived from both HPS2-iPSCs and cHPS2-iPSCs formed
AOs after three-dimensional co-culture with human fetal
lung fibroblasts (HFLFs). The expression levels of represen-
tative AT2 markers (SFTPC, SFTPB, and ABCA3) and
alveolar type 1 (AT1) markers (AQP5 and AGER) were not
significantly different among the AOs derived from control
hPSCs and HPS2-iPSCs and cHPS2-iPSCs (Figure 2B). The
fibrosis-related markers (TGFB1, ACTA2, SNAIL, and
TWIST) showed no differences between HPS2-AOs and
cHPS2-AOs (Figure 2C), consistent with the findings of
the animal study in that the Ap3b1 mutant (Pearl) mice
did not develop PF spontaneously (Young et al., 2007).
Utility of NaPi2b as a Surface Antigen for the
Subculture of AOs
NaPi2b encoded by SLC34A2 is a multi-transmembrane
protein expressed on AT2 cells, and MX35 is a monoclonal
antibody that recognizes its extracellular domain (Yin
et al., 2008). IF staining showed that SFTPC+ cells in both
adult and fetal human lung tissues expressed NaPi2b (Fig-
ure S2E). We investigated whether this antibody was useful
for the isolation of AT2 cells from the adult human lung.
The proportion of SFTPC+ AT2 cells was 84.2% ± 6.5% in
the NaPi2bhigh population and 84.8% ± 3.6% in the HT2-
280high population (Figures S2F–S2I). qRT-PCR showed
that the AT2 marker expression was concentrated in the
Figure 1. Generation of HPS2-iPSCs and cHPS2-iPSCs
(A) Schematic overview of the generation of HPS2-iPSCs and cHPS2-iPSCs.
(B) Different mutations in each allele of the patient fibroblasts.
(C) Strategy for correcting the mutation in exon 18.
(D) Sequence data of exon 18 in donor fibroblasts, HPS2-iPSCs, and cHPS2-iPSCs. The mutation was corrected in cHPS2-iPSCs.
(E) qRT-PCR of AP3B1 in each cell line. 201B7 was used for control iPSCs (mean ± SEM, n = 3 independent experiments). A one-way ANOVA
with Tukey’s multiple comparisons test was used. *p < 0.05; n.s., not significant.
(F) IF staining of the b3A subunit of AP-3 complex in each iPSC line. 201B7 was used for control iPSCs. Scale bars, 100 mm.
(G) Surface CD63 expression in control iPSCs, HPS2-iPSCs, and cHPS2-iPSCs. 201B7 was used for control iPSCs.
(H) Median fluorescence intensity of CD63-Alexa647 (mean ± SEM, n = 3 independent experiments). A one-way ANOVA with Tukey’s
multiple comparisons test was used. *p < 0.05; n.s., not significant.
See also Figure S1.
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Figure 2. Generation of iPSC-derived AOs and Their Expansion Based on the Expression of NaPi2b
(A) Schematic overview of the generation of hPSC-derived AOs.
(B) qRT-PCR of AT1 and AT2 markers in AOs (P0) (mean ± SEM, n = 3 independent experiments). Kruskal-Wallis with Dunn’s multiple
comparisons test was used. n.s., not significant.
(legend continued on next page)
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NaPi2bhigh population, whereas AT1 and airway markers
were enriched in the NaPi2blow population, suggesting
that AT2 cells were selectively isolated in the NaPi2bhigh
population (Figures S2J).
NaPi2b was also expressed on the luminal surface of
SFTPC+ cells in hPSC-derived AOs regardless of the AP3B1
genotype (Figure 2D). The NaPi2bhigh population con-
tained more SFTPC+ cells than the NaPi2blow population
(Figures S3A–S3C), which was supported by the different
levels of SFTPC and SLC34A2 in both populations (Fig-
ure 2E). When NaPi2bhigh cells were co-cultured with
HFLFs, AT2 cells were successfully subcultured in AOs,
which also expressed AT2 cell markers with a stepwise in-
crease of SLC34A2 (Figures 2F–2H). In P2-AOs, NaPi2b
was maintained on the luminal surface of SFTPC+ cells in
both HPS2-AOs and cHPS2-AOs, similarly to P0-AOs (Fig-
ure 2G). We also investigated HT2-280 for isolating AT2
cells in AOs, but the number of HT2-280+ cells was too
small for subculture or analysis (Figures S3D and S3E).
These findings indicated that anti-NaPi2b monoclonal
antibody (MX35) was more useful than HT2-280 for sub-
culturing AT2 cells in hPSC-derived AOs.
Abnormal Distribution and Aberrant Structures of LBs
in HPS2-AOs
LBs in AOs were examined via live cell imaging using Lyso-
Tracker (LT), a fluorescent probe used for visualizing LBs
(Haller et al., 1998; Yamamoto et al., 2017). Interestingly,
whereas the LT+ organelles were gathered on the apical
side of the constituent epithelial cells in control AOs and
cHPS2-AOs, they were distributed randomly in HPS2-AOs
(Figures 3A–3C). This distributional difference was more
clearly observed in P2-AOs than in P0-AOs (Figures 3A
and S3F). In addition, the LT+ organelles in HPS2-AOs
seemed enlarged in P2-AOs (Figures 3A and 3B). In IF
staining, ABCA3, a limiting membrane protein of the LBs
(Yamano et al., 2001), was located on apically distributed
vesicles in DCLAMP+ cells of cHPS2-AOs whereas it was
located on the enlarged and randomly distributed vesicles
in those of HPS2-AOs, suggesting that LT+ organelles corre-
sponded to LBs (Figure 3D). In electron microscopy, giant
LBs (>5 mm in diameter) were occasionally observed in
HPS2-AOs, whereas the LBs in control AOs or cHPS2-AOs
were of a normal size (1–2 mm in diameter) (Figure 3E).
Furthermore, abnormally formed lysosome-like organelles
were frequently observed in HPS2-AOs (Figure S3G),
consistent with a previous report on Pearl mice (Zhen
et al., 1999). We therefore concluded that altered distribu-
tion and enlargement of LBs with abnormally formed or-
ganelles were the phenotype of HPS2-AOs.
Impaired Surfactant Secretion from HPS2-AO-Derived
Cells
As decreased secretion of pulmonary surfactant was re-
ported in HPS1 and HPS2 double-mutant mice (Pale Ear/
Pearl) (Guttentag et al., 2005), we evaluated the pulmonary
surfactant secretion of HPS2-AOs and cHPS2-AOs. EpCAM+
cells of both AOs were reseeded on coverglass chambers,
and live cell imaging was performed after staining with
LT and FM1-43, a fluorescent probe that labels free lipids
and which has been used to evaluate the exocytosis of
LBs from primary AT2 cells (Haller et al., 1998) (Figure 4A).
After stimulation with a secretagog cocktail, the fluores-
cence intensity of FM1-43 was increased in cHPS2-AO
epithelial cells but not in HPS2-AO epithelial cells (Figures
4B and 4C; Video S1). Consistently, z-stack images sug-
gested that more FM1-43 stained vesicles were secreted
from cHPS2-AO cells than from HPS2-AO cells (Figure 4D).
Furthermore, the concentration of phosphatidylcholine in
culture supernatant was significantly reduced in HPS2-AO-
derived cells (Figure 4E). These findings suggested that
HPS2-AO cells were less prone to secrete the surfactant,
consistent with the findings that Pearl mice showed
decreased secretion of kidney lysosomal enzymes (Novak
and Swank, 1979). In addition, there was no significant
change in the levels of FM1-43 augmentation between
the enlarged and normal LBs in HPS2-AOs (Figures 4B,
S3H, and S3I), suggesting that impaired LB secretion in
HPS2-AO cells was caused by dysfunction of the AP-3 com-
plex rather than the size of the LBs.
DISCUSSION
Weestablished theHPS2-iPSCs frompatient fibroblasts and
their gene-corrected cHPS2-iPSCs. Although the mutation
in exon 15 persisted in cHPS2-iPSCs, we consider the re-
sults obtained from the experiments using cHPS2-iPSCs
(C) qRT-PCR of fibrosis-related markers in AOs (P0) (mean ± SEM, n = 5 independent experiments). The Mann-Whitney test was used. n.s.,
not significant.
(D) Confocal IF staining of AOs (P0) derived from HPS2-iPSCs and cHPS2-iPSCs. Scale bars, 10 mm.
(E) qRT-PCR of SFTPC and SLC34A2 in NaPi2bhigh and NaPi2blow cells sorted from AOs (P0) (mean ± SEM, n = 3 independent experiments).
(F) Schematic overview of the subculture of NaPi2bhigh cells in AOs. NaPi2bhigh cells were passaged every 2 weeks.
(G) Confocal IF staining of AOs (P2) subcultured using anti-NaPi2b antibodies. Scale bars, 10 mm.
(H) qRT-PCR of AT2 markers in subcultured AOs (P0–P2) (mean ± SEM, n = 3 independent experiments).
See also Figures S2 and S3.
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to be reliable for three reasons. First, the increased CD63 in
HPS2-iPSCs was restored in cHPS2-iPSCs, suggesting that
AP-3 complex works sufficiently, even in the presence of
the exon 15mutation. Second, HPS2 is an autosomal reces-
sive disease and it was reported that the mother of the
donor, who had the nonsense mutation in exon 15 but
not in exon 18, had no symptoms of HPS2 (Huizing
et al., 2002). Finally, the amount of AP3B1 mRNA is very
low in HPS2-iPSCs due to NMD, and the aberrant protein
production is negligibly low. For these reasons, we consider
cHPS2-iPSCs to be an appropriate control for HPS2-iPSCs.
Themechanism underlying the formation of giant LBs in
HPS is unknown. Since there was a report suggesting that
enlarged lysosomes have impaired motility, even in wild-
type cells (Perou and Kaplan, 1993), we investigated
whether the size of LBs affected the FM1-43 augmentation
Figure 3. Morphological Features of HPS2-AOs and cHPS2-AOs
(A) Live cell imaging of AOs (P2) derived from control iPSCs, HPS2-iPSCs, and cHPS2-iPSCs, respectively. Scale bars, 10 mm.
(B) Schematic illustration of the pattern of LT+ organelle distribution in AOs.
(C) Quantitative analysis of LT+ organelles distributed basally in the spheroids (mean ± SEM, n = 22–32 from three independent exper-
iments). Kruskal-Wallis with Dunn’s multiple comparisons test was used. *p < 0.05.
(D) Confocal IF staining of ABCA3 and DCLAMP in HPS2-AOs and cHPS2-AOs (P2). Scale bars, 10 mm.
(E) Electron micrographs of AOs (P2) from each cell line. Scale bars, 1 mm.
See also Figure S3.
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Figure 4. LB Secretion Assay for AT2 Cells Derived from HPS2-iPSCs and cHPS2-iPSCs
(A) Schematic overview of the LB secretion assay.
(B) Confocal images of HPS2-AO(P0) and cHPS2-AO(P0) epithelial cells at 30 and 330 s after stimulation with secretagogs. Phase-contrast
images show the location of LBs and nuclei. Scale bars, 10 mm.
(legend continued on next page)
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levels in the HPS2-AO epithelium. Our results suggested
that the impaired LB secretion in HPS2-AO cells was caused
by the dysfunction of AP-3 complex rather than the size of
the LBs, which was consistent with the idea that AP-3 is
required for the sorting of proteins involved in the move-
ment of LROs along microtubules (Clark et al., 2003). We
considered that the enlargement of the LBs in HPS2-AOs
is a result of impaired surfactant secretion rather than its
cause. In addition, the abnormal distribution of LBs seen
in HPS2-AOs was analogous to the previous report on ab-
normalities in cytotoxic T lymphocytes (CTLs) in HPS2 pa-
tients, in which lytic granules, the LROs of CTLs, failed to
move to the secretory surface of the cells (Clark et al.,
2003).
Pulmonary surfactant plays critical roles in the mainte-
nance of the alveolar environment and its deficiency
causes respiratory distress syndrome (RDS) in newborns.
In addition, mutations in genes associated with LBs, such
as ABCA3 and SFTPB, are typically lethal in neonates
because of defective surfactant metabolism (Whitsett
et al., 2015). In this study, the stimulated secretion of pul-
monary surfactant was decreased in HPS2-AOs, but it was
reported that HPS2 patients do not present RDS and that
Pearl mice do not develop RDS or PF spontaneously in their
lifetimes (Young et al., 2007). Our finding that basal secre-
tion was preserved, not abrogated, in HPS2-AOs might
explain why HPS2 patients and Pearl mice do not present
RDS. Further studies are needed to investigate this discrep-
ancy. It also remains to be elucidated whether decreased
surfactant secretion may play some roles in the pathogen-
esis of PF in HPS2 patients, although decreased surfactant
secretion has been reported in PF patients (Schmidt et al.,
2002).
In this study, we validated three methods related to lung
stem cell research. First, for the isolationNKX2-1+ lung pro-
genitor cells, CPM-based and CD47-based methods were
compared (Gotoh et al., 2014; Hawkins et al., 2017). The
CPMhigh population contained more NKX2-1+ cells than
the CD47highCD26low population, although our induction
protocol had originally been developed to fit CPM-based
sorting. The second involved the isolation of AT2 cells
from the adult human lung by the anti-NaPi2b antibody.
Currently, HT2-280 is used for isolating AT2 cells from
adult lung (Gonzalez et al., 2010). We demonstrated that
the proportions of SFTPC+ AT2 cells in the NaPi2bhigh
and the HT2-280high populations were equivalent and
that other AT2 cellmarkers were enriched in theNaPi2bhigh
population. Finally, we demonstrated that the anti-NaPi2b
antibody was also useful for passaging hPSC-derived AOs
without establishing reporter cell lines. Aswe previously re-
ported, the SFTPC expression in hPSC-AOs decreased
without passaging, and it was necessary to isolate SFTPC+
cells and reseed them into Matrigel with HFLFs in order
to maintain the AT2 marker expression (Yamamoto et al.,
2017). Although this is a limitation of the current hPSC-
AO system, progress has been made in maintaining more
AT2 markers in organoids in comparison with conven-
tional two-dimensional culture. In this study, P2-AOs
were used to analyze the distribution or morphological
characteristics of LBs because P2-AOs contained more LBs
than P0-AOs (Figure 3). On the other hand, to analyze
the LB secretion (Figure 4), EpCAM+ cells, not NaPi2bhigh
cells, from P0-AOs were used to obtain sufficient cells.
It is necessary for disease modeling to recapitulate the
functions of the cells responsible for the disease. While
hPSC-derived lung organoids including both airway and
alveolar lineages have been reported (Chen et al., 2017),
there are few reports of organoids focusing on alveolar cells
and their functions (Jacob et al., 2017; Yamamoto et al.,
2017). To our knowledge, no reports have verified the secre-
tion of pulmonary surfactant in both hPSC-derived AOs
and in HPS patient-derived cells. Human iPSC-derived
AT2 cells might overcome the limited availability and aid




After AOs or reseeded cells were stainedwith fluorescent probes, all
of the samples were examined under an FV10i-LIV confocalmicro-
scope (Olympus) with a 603 objective under 5% CO2 at 37
C. For
the LB secretion assay, the medium was supplemented with a sec-
retagog cocktail so that the final concentration of each component
was 5 mM forskolin, 15 mM ATP, 150 nM ionomycin, and 150 nM
phorbol 12-myristate 13-acetate. For further details, see Supple-
mental Experimental Procedures.
Ethics
The use of H9 hESCs was approved by the Ministry of Education,
Culture, Sports, Science and Technology (MEXT), Japan. The
animal experiments were approved by the Animal Research
(C) Quantitative comparison of the FM1-43 augmentation levels (mean ± SEM, n = 7–10 from three independent experiments). Kruskal-
Wallis with Dunn’s multiple comparisons test was used. *p < 0.05; n.s., not significant.
(D) z-stack images of LT and FM1-43 staining before and after stimulation with secretagogs. Scale bars, 5 mm.
(E) Phosphatidylcholine (PC) concentration of the supernatant of secretagog-stimulated epithelial cells from AOs (mean ± SEM, n = 11
from 11 independent experiments). Kruskal-Wallis with Dunn’s multiple comparisons test was used. *p < 0.05; n.s., not significant.
See also Figure S3 and Video S1.
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Committee of Kyoto University. The use of human lung samples
was approved by the Ethics Committee of Kyoto University
Graduate School and Faculty of Medicine.
Statistical Analyses
All error bars indicate the SEM. Quantified data represent the find-
ings of three or more independent experiments. The statistical
tests used are shown in each legend. All statistical analyses were
performed using the Prism7 software program (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, four tables, and one video and can be
found with this article online at https://doi.org/10.1016/j.stemcr.
2019.01.014.
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